The big challenge in 21st century neurology is to develop treatments that can slow, stop, or reverse the loss of brain cells in neurodegenerative diseases like the dementias, motor neurone disease, and MS.

Part of the reason why we don't already have these treatments is because we lack the tools to measure neuroprotection and brain repair in clinical trials. My work aims to develop the measurement tools we need.

Separately, by defining diseases through their symptoms rather than through the underlying (patho)biology, most patients in any regenerative neurology trial will have little prospect of benefit. I also work on methods to ""stratify" neurodegenerative diseases so that the right person gets the right treatment at the right time.